209809-36-9

Upstream product

• 40843-79-6 4-(4-chlorophenoxy)-2-(2-propenyl)phenol 
• 352-33-0 1-Chloro-4-fluorobenzene 
• 21567-18-0 4-(4-chlorophenoxy)phenol 
• 40843-78-5 3-[4-(4-chlorophenoxy)phenoxy]-1-propene 
• 123-31-9 hydroquinone 
• 459-57-4 4-fluorobenzaldehyde 
• 61343-99-5 4-(4'-chlorophenoxy)benzaldehyde 
• 106-48-9 4-chloro-phenol 

Downstream Products

• 909543-15-3 4-(4-chlorophenoxy)-2-propylphenyl trifluoromethanesulfonate 
• 209808-64-0 2-(2-(4-(4-Chlorophenoxy)-2-propylphenoxy)ethyl)indole-5-acetic acid 
• 656235-28-8 5-(4-{3-[4-(4-chloro-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-2-imino-thiazolidin-4-one 
• 606966-68-1 (3-{3-[4-(4-chloro-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-hydroxy-acetic acid methyl ester 
• 592508-56-0 (4-{3-[4-(4-chloro-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-hydroxy-acetic acid methyl ester 

Relevant academic research and scientific papers

ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES

Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia

PROCESS FOR THE PRODUCTION OF ANTIDIABETIC OXAZOLIDINEDIONES

The present invention provides a convergent process for the preparation of a family of antidiabetic phenoxy-substituted phenoxybenzyl oxazolidinediones shown as structure I. The compounds are selective PPAR gamma partial agonists (SPPARM's), which are use

FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY

Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obes

Selective displacement of aryl fluorides with hydroquinone: Synthesis of 4-phenoxyphenols

The selective displacement of a variety of aryl fluorides with hydroquinone has been achieved to give substituted 4-phenoxyphenols 3. In some cases the addition of 18-crown-6 resulted in a significant rate enhancement, and the reactions could be carried out at lower temperature. One of these derivatives, 3a (X = Cl) was converted to 2-propyl-4-(4-chlorophenoxy)phenol 2a, a precursor to the PPARγ receptor agonist 1.

ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES

Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones of formula (I) are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents

A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARα/γ agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia.

Antidiabetic agents

The instant invention is concerned with aryl and heteroaryl oxyacetic acid type compounds which are useful antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and related diseases and for lowering triglyceride levels are also disclosed.